Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $62.65, up 1.54% from its previous closing price of $61.70. In other words, the price has increased by $1.54 from its previous closing price. On the day, 0.93 million shares were traded. TMDX stock price reached its highest trading level at $63.74 during the session, while it also had its lowest trading level at $61.802.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 8.20. In the meantime, Its Debt-to-Equity ratio is 2.47 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 02 ’24 when Khayal Tamer I sold 1,084 shares for $86.40 per share. The transaction valued at 93,658 led to the insider holds 20,843 shares of the business.
Khayal Tamer I sold 1,458 shares of TMDX for $131,278 on Nov 11 ’24. The Chief Commercial Officer now owns 20,843 shares after completing the transaction at $90.04 per share. On Nov 05 ’24, another insider, Basile Edward M, who serves as the Director of the company, sold 6,750 shares for $83.55 each. As a result, the insider received 563,994 and left with 732 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2102627968 and an Enterprise Value of 2258797568. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.12, and their Forward P/E ratio for the next fiscal year is 42.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.34 while its Price-to-Book (P/B) ratio in mrq is 10.02. Its current Enterprise Value per Revenue stands at 5.632 whereas that against EBITDA is 44.171.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $59.72. The 50-Day Moving Average of the stock is -28.75%, while the 200-Day Moving Average is calculated to be -48.08%.
Shares Statistics:
It appears that TMDX traded 1.85M shares on average per day over the past three months and 1610170 shares per day over the past ten days. A total of 33.56M shares are outstanding, with a floating share count of 32.43M. Insiders hold about 3.39% of the company’s shares, while institutions hold 109.83% stake in the company. Shares short for TMDX as of 1732838400 were 9291382 with a Short Ratio of 5.03, compared to 1730332800 on 8426990. Therefore, it implies a Short% of Shares Outstanding of 9291382 and a Short% of Float of 33.67.
